Maxim Group LLC Acts as co-manager for Heat Biologics in its $7 Million Underwritten Public Offering of Common Stock and Warrants

Heat Biologics, Inc. (“Heat”) (HTBX), a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate patients’ immune systems against cancer, today announced the pricing of an underwritten public offering consisting of 20,000,000 shares of Common Stock together with Warrants to purchase 10,000,000 shares of Common Stock at a combined price to the public of $0.35. The gross proceeds to the Company from this offering are expected to be approximately $7,000,000, before deducting underwriting discounts, commissions and other offering expenses. The Warrants will have an exercise price of $0.385, will be exercisable upon issuance and will expire 14 months from the date of issuance. Heat Biologics, Inc. has granted the underwriters a 45-day option to purchase up to 3,000,000 additional shares of Common Stock and/or additional Warrants to purchase up to 1,500,000 shares of Common Stock to cover over-allotments, if any. The offering is expected to close on Tuesday, January 21, 2020, subject to customary closing conditions.

A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering.

Brookline Capital Markets, a division of Arcadia Securities, LLC and Maxim Group LLC are acting as co-managers for the offering.

A registration statement on Form S-1 (File No. 333-234105) relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on January 16, 2020 and is available on the SEC’s website located at This offering is being made only by means of a prospectus. Electronic copies of the prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus and the other documents that Heat Biologics, Inc. has filed with the SEC that are incorporated by reference in such prospectus, which provides more information about Heat Biologics, Inc. and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Heat Biologics

Heat Biologics is a clinical-stage biopharmaceutical company developing novel therapeutics designed to activate a patient’s immune system against cancer using CD8+ “Killer” T-cells. Pelican Therapeutics, Inc., a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system.

Nam sed lectus nec lectus posuere malesuada in in urna. In erat mauris, condimentum quis sodales a, consequat eu erat. Curabitur maximus nulla erat, non dignissim est laoreet sed. Aliquam mollis aliquet libero efficitur iaculis. Proin ac maximus nisi. Nullam leo turpis, luctus quis leo eget, volutpat dictum nulla. Quisque ut magna elementum lacus congue consectetur. Nullam vitae auctor neque.

Cras leo risus, aliquet ac augue in, laoreet interdum erat. Quisque ante libero, ultrices vitae iaculis sit amet, vestibulum scelerisque nulla. Quisque lorem urna, faucibus at varius eu, lobortis eu tellus. Aenean rutrum nisl et erat luctus laoreet. Aenean at maximus justo, et mollis quam. Suspendisse sit amet arcu mi. Etiam vulputate efficitur molestie. Nam fermentum venenatis odio quis feugiat. Morbi felis dolor, dictum efficitur felis et, finibus varius dolor. Etiam ipsum nibh, gravida vitae nisl et, lacinia ultricies tellus. Donec laoreet consequat odio vel luctus. Nam gravida eros non tellus varius sagittis. Fusce eget urna non dolor luctus tristique. Aliquam erat volutpat.

Mauris at nisi mauris. Nam convallis vitae mi at rutrum. Cras bibendum risus ante, a faucibus velit convallis sit amet. Sed a convallis augue, at elementum neque. Donec gravida et sem id euismod. Suspendisse potenti. Aliquam feugiat ipsum vitae commodo accumsan. Duis ac arcu id nibh dictum tincidunt nec posuere diam. Maecenas sem elit, laoreet dapibus diam nec, congue interdum nisi. Nullam non enim at risus pellentesque consectetur. Nullam arcu leo, rutrum vel lorem eget, imperdiet pellentesque est.

Praesent eleifend purus quis nisl fermentum, vel imperdiet urna ornare. Donec in quam euismod, tempus odio nec, convallis tellus. Mauris vehicula posuere faucibus. Maecenas ac accumsan nulla. Vivamus molestie mi tortor, in mollis orci tincidunt ac. Donec hendrerit lacus et nunc luctus, ac molestie elit cursus. Curabitur venenatis lobortis nisl ac tempor. Nulla vitae mi in tortor volutpat placerat. Sed sit amet tellus sollicitudin, tempor velit in, pharetra tortor. Sed id porta metus, egestas viverra neque. Cras imperdiet pellentesque lacus, non euismod urna imperdiet sed. In hac habitasse platea dictumst.

Integer aliquam quis odio in pellentesque. Nullam vehicula finibus volutpat. Ut mollis nisl vitae rhoncus venenatis. Fusce et erat imperdiet, facilisis nulla lacinia, pharetra augue. Nam nec mattis dolor. In ultrices cursus luctus. Fusce eleifend diam turpis. Duis non consectetur erat.

Related News

Scroll to Top